Trials / Completed
CompletedNCT03003039
A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 85 (actual)
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is the area under the curve (AUC) for GB241 and rituximab concentrations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GB241 | Single intravenous infusion (IV) 375 mg/m2 |
| BIOLOGICAL | Rituximab | Single intravenous infusion (IV) 375 mg/m2 |
Timeline
- Start date
- 2017-06-05
- Primary completion
- 2019-05-20
- Completion
- 2019-05-20
- First posted
- 2016-12-26
- Last updated
- 2021-03-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03003039. Inclusion in this directory is not an endorsement.